Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome

What Was Tested

Researchers studied Exenatide and Ghrelin in this clinical trial publication.

The objective of this study is to determine the effect of a 6-month trial of exenatide on appetite, weight and gut hormones in youth with PWS.

Who Took Part

The age groups tagged for this paper are teenagers, young adults and adults, both men and women.

Ten overweight and obese subjects with PWS (13-25 years) were recruited for a 6-month open-label, non-randomized, longitudinal study conducted at Children's Hospital Los Angeles.

How the Study Was Run

The researchers set it up as an open-label study.

Nothing was hidden in this open-label Exenatide study: the participants and staff both knew the treatment.

A time span of 6 months appears in the methods.

Weight, body mass index (BMI), truncal fat, appetite and plasma acylated ghrelin were measured over 6 months.

Mixed meal tolerance tests were performed at 0 and 6 months.

What Was Measured

The subject headings attached to it are Appetite, Body Mass Index, Exenatide, Ghrelin, Hyperphagia, Incretins and Longitudinal Studies.

Author keywords: Byetta and Prader-Willi syndrome.

What This Means in Plain Language

The paper is an open-label study of Exenatide and Ghrelin over 6 months.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (Pediatric obesity), a journal based in England.

More context: the Exenatide compound page and the Ghrelin compound page.